Finance

Lists
STOK:NASDAQ
Stoke Therapeutics Inc
$29.81
-0.60%
(-0.18) 1D
$29.81
0.00% (0.00)
After hours
Closed: Sep 4, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for STOK...
Open
$29.41
High
$30.03
Low
$29.14
Mkt. cap
1.92B
Avg. vol.
882.35K
Volume
714.06K
52-wk high
$40.22
52-wk low
$19.55
EPS
-$3.36
Beta
1.23
Shares outstanding
64.53M
No. of employees
170
Open
$29.41
High
$30.03
Low
$29.14
Mkt. cap
1.92B
Avg. vol.
882.35K
Volume
714.06K
52-wk high
$40.22
52-wk low
$19.55
EPS
-$3.36
Beta
1.23
Shares outstanding
64.53M
No. of employees
170
News stories
From web sources and news partners
About Stoke Therapeutics Inc
CEO-
Employees170
Founded2014
HeadquartersBedford, Massachusetts, United States
SectorBiotechnology
Websitestoketherapeutics.com
Analyst ratings
Based on 10 analysts giving stock ratings to STOK in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for STOK in the last 3 months.
Highest
Current $29.81
$60.00 (+101.27%)
Average
$45.40 (+52.30%)
Lowest
$35.00 (+17.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jessica Fye
J.P. Morgan
Buy
Initiated
$40.00
+34.2%
08/21/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$58.00
+94.6%
08/12/2026
Rudy Li
Wolfe Research
Buy
Maintained
$40.00
+34.2%
08/03/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$50.00
+67.7%
08/04/2026
Kevin Strang
Goldman Sachs
Buy
Maintained
$44.00
+47.6%
08/03/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$60.00
+101.3%
08/04/2026
Thomas Shrader
BTIG
Buy
Maintained
$39.00
+30.8%
08/03/2026
Joseph Stringer
Needham
Buy
Maintained
$40.00
+34.2%
08/04/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$35.00
+17.4%
08/03/2026
Unknown Analyst
Jefferies
Buy
Maintained
$48.00
+61%
07/06/2026
Marc Goodman
Leerink Partners
Buy
Maintained
-
-
06/02/2026
Laura Chico
Wedbush
Buy
Maintained
$38.00
+27.5%
05/08/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$60.00
+101.3%
05/07/2026
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.93 / -$0.78
-19.09%miss
Revenue / Est. (USD)
9.32M / 5.09M
+83.20%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
10.63M
1.40M
6.23M
9.32M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
37.70M
41.70M
39.67M
49.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.03M
21.15M
19.97M
25.25M
Operating expense
53.72M
62.84M
59.65M
74.75M
Total operating expenses
53.72M
62.84M
59.65M
74.75M
Operating income
-43.09M
-61.44M
-53.42M
-65.43M
Other non operating income
3.00K
-110.00K
18.00K
308.00K
EBT including unusual items
-39.62M
-57.93M
-50.00M
-61.62M
EBT excluding unusual items
-39.62M
-57.93M
-50.00M
-61.62M
Income tax expense
-1.28M
-
-
-
Effective tax rate
3.23%
-
-
-
Other operating expenses
-
-
-
-
Net income
-38.35M
-57.93M
-50.00M
-61.62M
Net profit margin
-360.68%
-4,132.24%
-802.75%
-660.78%
Earnings per share
-0.65
-0.97
-0.79
-0.93
Interest and investment income
3.47M
3.62M
3.42M
3.52M
Interest expense
-3.00K
-3.00K
-23.00K
-17.00K
Net interest expenses
3.46M
3.62M
3.40M
3.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
-42.65M
-61.03M
-52.98M
-64.97M
Gain or loss from assets sale
-8.00K
153.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps